Last checked at 17 Apr 2024 14:23
Bivictrix granted FDA orphan drug status for rare cancer treatment
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said its BVX001 drug has been granted special status by the US Food and Drug Administration.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Bivictrix Thera Share News (BVX)
BVX Share
Price
BVX Share
News
BVX Share
Chat
BVX Share
Trades3
BVX
Live RNS
BVX Share
Charts
BVX Level 2
Console
BVX Live
Share Price
BVX Broker
Ratings
BVX Directors
Deals
BVX Financial
Diary
BVX
Fundamentals
BVX Short
Positions
BVX
Media
Bivictrix Thera Information
Share Price Information for Bivictrix Thera (BVX)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
11.50
Bid:
11.00
Ask:
12.00
Change:
0.00 (0.00%)
Spread:
1.00 (9.091%)
Open:
11.50
High:
11.50
Low:
11.50
Prev. Close:
11.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.30 Nov 2023 12:08
IN BRIEF: Bivictrix selects final sequences for lead tumour programme
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected for its second programme BVX002, an antibody drug conjugate or ADC targeting solid tumour indications. Emerging data identifies high-grade serous ovarian cancer as one of the lead indications. Company says it is on track to identify the development lead in 2024. Says findings represent "significant unmet need and commercial potential for BVX002".
Read more15 Nov 2023 13:05
TRADING UPDATES: BiVictriX patent boost; 4Global deal extended
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more15 Nov 2023 12:55
BiVictriX gets patent for its lead asset in Japan
(Sharecast News) - BiVictriX Therapeutics has received a patent grant from the Japanese Patent Office (JPO) for its lead asset BVX001, it announced on Wednesday.
Read more12 Oct 2023 13:44
BiVictriX posts promising preclinical data on leukaemia candidate
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class 'Bi-Cygni' antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).
Read more12 Oct 2023 12:04
Bivictrix says BVX001 increases survival rates by more than double
(Alliance News) - Bivictrix Therapeutics PLC on Thursday said its Bi-Cygni antibody-drug conjugate, BVX001, showed survival rates more than doubled in a pre-clinical model of acute myeloid leukaemia.
Read more3 Oct 2023 12:06
Bivictrix hires new CFO as Alex Hughes steps down after seven months
(Alliance News) - Bivictrix Therapeutics PLC on Tuesday said it has appointed Adrian Howd as chief financial officer and chief business officer as CFO Alex Hughes is set to step down next Friday after just seven months in the role.
Read more3 Oct 2023 10:14
BiVictriX appoints Adrian Howd as its new finance chief
(Sharecast News) - Biotechnology developer BiVictriX Therapeutics announced the appointment of Dr Adrian Howd as its chief financial officer (CFO) and chief business officer (CBO) on Tuesday.
Read more19 Sep 2023 17:30
TRADING UPDATES: AEW UK REIT appoints new chair; Oberon raises money
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more23 Aug 2023 14:29
BiVictriX secures US patent for flagship therapeutic asset
(Sharecast News) - Cancer treatment developer BiVictriX Therapeutics has secured a significant patent from the United States Patent and Trademark Office (USPTO), it announced on Wednesday, for its flagship therapeutic asset, BVX001.
Read more23 Aug 2023 10:51
AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more23 Aug 2023 09:30
Bivictrix Therapeutics granted US patent for cancer drug BVX001
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said it has been granted a US patent for lead asset BVX001.
Read more19 Jul 2023 19:30
UPDATE: Bivictrix Therapeutics raises GBP2.1 million through fundraise
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said it has raised GBP2.1 million through a placing and subscription of 16.4 million shares.
Read more19 Jul 2023 14:12
IN BRIEF: Bivictrix to raise more than GBP2 million via placing
Bivictrix Therapeutics PLC on Wednesday - Macclesfield, England-based biotechnology company focusing on cancer therapies - Announces a proposed fundraise of over GBP2 million by way of a conditional placing to investors. The placing will raise GBP1.2 million before expenses through the issue of 9.2 million shares at 13 pence per share. Adds the subscription of shares will raise around GBP800,000 before expenses through the issue of 6.8 million new shares. Says issue of shares is subject to shareholder approval at the general meeting set to take place on August 8.
Read more17 Jul 2023 13:57
Bivictrix Therapeutics hails positive data in final leukaemia study
(Alliance News) - BiVictriX Therapeutrics PLC announced on Monday that it had received positive final data from a second in vivo efficacy study of BVX001, an antibody drug for treatment of acute myeloid leukaemia.
Read more